IBOV 175,664.62 ▲ 0.30% IPSA 11,445.90 ▼ 0.22% IPC MEX 65,484.32 ▼ 0.53% MERVAL 2,979,472 ▼ 0.72% COLCAP 2,457.87 ▼ 1.28% BVL PERÚ 60,779.49 ▼ 1.40% USD/BRL5.21▲ 0.23% USD/MXN17.03▼ 0.02% USD/CLP930.58— 0.00% USD/COP3,202▲ 1.26% USD/PEN3.35▼ 0.01% USD/ARS1,512— 0.00% USD/UYU40.27▲ 1.47% USD/PYG5,900▲ 1.27% USD/BOB11.78▲ 3.30% USD/DOP58.61▲ 0.96% USD/CRC446.65▲ 0.97% USD/GTQ7.62▲ 2.20% USD/HNL26.84▲ 0.40% USD/NIO36.62— 0.00% USD/VES789.69▼ 0.54% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.72▲ 0.84% EUR/BRL6.01▲ 0.17% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 175,664.62 ▲ 0.30% IPSA 11,445.90 ▼ 0.22% IPC MEX 65,484.32 ▼ 0.53% MERVAL 2,979,472 ▼ 0.72% COLCAP 2,457.87 ▼ 1.28% BVL PERÚ 60,779.49 ▼ 1.40% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Sunday, August 30, 2026

According to new study on mRNA vaccines, harm-benefit ratio is negative

By · June 30, 2022 · 2 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – When drugs are used, the principle is that the benefits must be more significant than the harms from adverse side effects.

In the case of the experimental mRNA Covid vaccines from Moderna and Pfizer, a large number of reported (sometimes very serious) side effects should only be accepted if they provide as much protection against hospitalization and death from Covid-19 as is readily claimed.

Read also: Check out our coverage on curated alternative narratives

But a recently published study suggests that this is not the case. This study also features high-profile authorship from the United States (including Robert M. Kaplan of Stanford University’s School of Medicine), which certainly adds to the weight of this paper. The introduction also states:

Pfizer and Moderna mRNA-COVID-19 vaccines were associated with an increased risk of serious adverse events of particular interest, with absolute risk increases of 10.1 and 15.1 per 10,000 vaccinees, respectively, compared with baseline placebo values of 17.6 and 42.2 (95% CI -0.4 to 20.6 and -3.6 to 33.8, respectively).

Taken together, the mRNA vaccines were associated with an absolute increase in the risk of serious adverse events of particular interest of 12.5 per 10,000 (95% CI 2.1 to 22.9). The increased risk of serious adverse events of specific interest exceeded the risk reduction for COVID-19 hospitalization compared with the placebo group in both the Pfizer and Moderna trials (2.3 and 6.4 per 10,000 participants, respectively).

RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →

And as you can see from the tables below (more detailed tables can be found at the end of the study itself), the data is indeed startling:

In the “harm-benefit considerations,” it says: “In the Moderna trial, the excess risk of severe Adverse Events of Special Interests (AESIs) (15.1 per 10,000 participants) exceeded the risk reduction for Covid-19 hospitalizations compared with the placebo group (6.4 per 10,000 participants).”

“In the Pfizer trial, the excess risk of severe AESIs (10.1 per 10,000) exceeded the risk reduction for Covid-19 hospitalizations compared with the placebo group (2.3 per 10,000 participants).”

In other words, both the Moderna and Pfizer vaccines cause significantly more severe adverse events than they prevent severe Covid events.

You can download the study here.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.